Common questions about Fycampa (FAQ)
Q: Is Fycampa classified as a controlled substance?
Yes, Fycampa (perampanel) is classified as a Schedule III controlled substance by the U.S. Drug Enforcement Administration (DEA). The Schedule III classification reflects its established medical use along with a determined potential for abuse or physical dependence, a finding noted in regulatory studies.
Q: What is Fycampa used for besides epilepsy?
According to regulatory documents, the medicine is currently approved only for use as an add-on treatment for two specific types of epileptic seizures: partial-onset seizures and primary generalized tonic-clonic seizures. Official product information currently lists indications only for these specific uses.
Q: Can Fycampa cause issues with balance or walking?
Official safety data indicates that Fycampa can be associated with adverse reactions affecting movement and coordination. These effects, which include gait disturbance and ataxia (unsteadiness or lack of muscle control), are listed as common events. Official documentation notes that these events may occur mostly during the initial dose titration phase or following a dose increase.
Q: What is the difference between Fycampa and other older seizure medicines?
The mechanism of action for Fycampa (perampanel) is described as distinct from many other seizure medicines. Official documents state that it is a selective, non-competitive antagonist of the AMPA receptor (a type of protein in the brain). This action helps to reduce the over-activity of nerve signals that can trigger seizures.
Q: Are there any long-term effects of taking Fycampa?
The core evidence that established the drug's efficacy comes from short-term controlled studies. As the core evidence comes from short-term controlled studies, the certainty regarding long-term effects is limited compared to the initial double-blind data, even though some patients were observed in long-term extension studies.
Q: What should I do if I feel unusually aggressive after starting Fycampa?
Official documentation states that aggression or hostility are serious adverse reactions associated with Fycampa. If new or worsening behavioral changes are observed, official documents advise contacting a healthcare provider promptly. Close monitoring of mood and behavior is recommended, especially during the initial titration period.
Q: Is Fycampa a brand name, and what is the generic name?
Yes, Fycampa is the brand name. The generic name, or active ingredient, for the medicine is perampanel.
Q: What are the most common reasons why Fycampa treatment is stopped?
Official safety data indicates that psychiatric and behavioral reactions, such as hostility and aggression, were among the reasons for dose reduction or discontinuation in clinical trials, particularly at higher doses. These adverse reactions led to treatment modification in some participants.
Q: Do children or teenagers take Fycampa?
The medicine is approved for use in certain pediatric populations, depending on the type of seizure. For partial-onset seizures, it is approved for patients 4 years of age and older. For primary generalized tonic-clonic seizures, it is approved for patients 12 years of age and older.
Q: Does Fycampa cause weight gain or weight loss?
Official safety data lists weight gain as a common adverse reaction observed in clinical trials. Decreased appetite has been reported in regulatory documents, although weight gain is the effect listed as common.
Q: Can Fycampa affect my liver function?
Serious adverse reactions, including severe liver injury or Hepatotoxicity, have been reported with Fycampa. Official guidelines advise healthcare providers to closely monitor liver function in patients who have pre-existing hepatic impairment.
Q: Can people with kidney problems use Fycampa?
Official guidance states that Fycampa is not recommended for individuals with severe renal impairment or those undergoing haemodialysis. While no dose adjustment is generally required for mild impairment, official labeling advises caution and close monitoring for patients with moderate kidney impairment.
Q: What are the specific requirements for women who may become pregnant while taking Fycampa?
Women of reproductive potential are advised to use effective contraception during and for a period after treatment. If using hormonal contraceptives that contain levonorgestrel, the official requirement is to use an additional non-hormonal method of contraception, as Fycampa can reduce their effectiveness.
Q: Do you have to take Fycampa with food?
According to the official instructions, Fycampa is administered once daily and can be taken with or without food. This condition gives flexibility in when the medicine is consumed relative to meals.
Q: How does the body process or eliminate Fycampa?
The drug is extensively broken down (metabolized) in the liver, primarily through the CYP3A4 enzyme system. It is then removed from the body mainly through the urine and feces.
Q: What is Fycampa's history or how long has it been available?
Fycampa (perampanel) received initial regulatory approval in the United States in 2012. Since then, regulatory authorities have continuously updated the product information based on ongoing safety and efficacy data.
Q: What happens if Fycampa is stopped suddenly?
Regulatory information indicates that abrupt discontinuation may increase the risk of withdrawal symptoms and may lead to an increase in seizure frequency. Official protocols recommend that the dose be gradually reduced (tapered) when ending treatment.
Q: How does the effectiveness of Fycampa compare to placebo in clinical trials?
Clinical trials showed that patients receiving Fycampa had a greater reduction in seizure frequency compared to those who received a placebo. Specifically, the percentage of patients achieving a 50% or greater reduction in seizures (known as the responder rate) was higher in the Fycampa groups.
Q: Why is Fycampa a controlled substance in the US?
The US classification as a Schedule III controlled substance is based on the potential for abuse and dependence. This potential was determined during studies where supratherapeutic (high) doses produced subjective feelings of euphoria.
Q: Can taking Fycampa affect my mood even if I don't have a history of mental health issues?
Official warnings state that serious psychiatric and behavioral reactions, including aggression, anger, and hostility, have been reported in patients taking Fycampa with and without a prior history of mental health issues. Regulatory documents state that close monitoring for new or worsening mood changes is advised for all patients.
Q: Are there specific warnings for people with certain heart conditions using Fycampa?
Official warnings primarily focus on the liver, kidney, and psychiatric risks. However, clinical trials have sometimes excluded patients with pre-existing heart conditions, particularly those related to a prolonged QTc interval, a factor associated with an increased risk of abnormal heart rhythms.
Q: Is Fycampa used to treat non-epileptic seizures?
The approved uses for Fycampa are restricted to specific types of epileptic seizures—partial-onset and primary generalized tonic-clonic seizures. There is no regulatory documentation supporting its use for non-epileptic seizures.
Q: Does Fycampa interact with common over-the-counter pain relievers?
Official documentation advises caution when Fycampa is used with any other substance that causes sedation due to the potential for compounded depressant effects on the central nervous system (CNS). Caution is advised as this category may include components found in some common over-the-counter pain and cold medicines that possess sedative properties.
Q: Can Fycampa cause confusion or memory problems?
Yes, official adverse reaction data lists memory impairment as a common event observed in clinical trials. Other related cognitive effects, such as disorientation and a confusional state, have also been reported.
Q: What research exists about Fycampa use in older adults?
Official prescribing information includes specific recommendations for use in older adults. For example, dose increases (titration) should occur no more frequently than every two weeks for older adults. This adjustment reflects the specific considerations for use and tolerability needed for this population.
